Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC cancer Jg. 19; H. 1; S. 816 - 15
Hauptverfasser: Palma, David A., Olson, Robert, Harrow, Stephen, Correa, Rohann J. M., Schneiders, Famke, Haasbeek, Cornelis J. A., Rodrigues, George B., Lock, Michael, Yaremko, Brian P., Bauman, Glenn S., Ahmad, Belal, Schellenberg, Devin, Liu, Mitchell, Gaede, Stewart, Laba, Joanna, Mulroy, Liam, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Warner, Andrew, Slotman, Ben J., de Gruijl, Tanja D., Allan, Alison, Senan, Suresh
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 19.08.2019
BioMed Central Ltd
BMC
Schlagworte:
ISSN:1471-2407, 1471-2407
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!